Medable Inc., a leader in AI-powered clinical development technology, has introduced a new AI agent designed to ease the workload for principal investigators (PIs) by streamlining oversight of electronic clinical outcome assessment (eCOA) data. The Medable PI Summary Agent is the latest addition to the company’s growing suite of agentic AI tools, following the recent launch of its TMF and CRA agents, and underscores Medable’s rapid expansion of function-specific, AI-driven solutions in clinical research. The PI Summary Agent integrates directly into Medable’s eCOA platform, enabling real-time monitoring of participant data. It automatically generates concise, AI-powered summaries of each participant’s most recent eCOA inputs, highlighting key data points that require attention. This allows PIs to quickly assess patient status and ensure regulatory compliance without manually sifting through multiple reports or systems. “Regulators expect satisfactory oversight of remotely captured data, which has traditionally required PIs to manually verify content across numerous platforms,” said Dr. Pamela Tenaerts, Chief Medical Officer at Medable. “Our agent centralizes this process, delivering a clear, actionable summary of eCOA data while preserving full access to all raw data and maintaining human-in-the-loop control.” By surfacing critical patient information proactively, the agent supports timely decision-making and enhances transparency and traceability in data oversight. It is designed to operate without disrupting ongoing trial workflows, site operations, or participant engagement. The Medable PI Summary Agent is now available as part of the company’s eCOA platform. The company will showcase its broader strategy in leveraging agentic AI to reduce operational costs and accelerate clinical development at the SCOPE Summit, taking place February 2–5, 2026, in Orlando, Florida, at Booth #806. Andrew Mackinnon, a key leader at Medable, will present “From Tool to Teammate – Unlocking the Power of AI Agents” on Wednesday, February 4, at 11:15 a.m. Medable’s mission is to accelerate the delivery of effective therapies by transforming clinical research with digital innovation. Its platform has been deployed in nearly 400 trials across 70 countries and 120 languages, supporting more than one million patients globally. Recognized as a Leader in eCOA by Everest Group, Medable is a privately held, venture-backed company headquartered in Palo Alto, California. For more information, visit medable.com.